Скачать или смотреть Understanding Tricuspid Atresia

Check the newer version of this video!    • Understanding Tricuspid Atresia  

A brief (medical review) explanation on the Anatomy, Pathophysiology, Epidemiology and Treatment of Tricuspid Atresia, a cardiac malformation derived from a failure of the tricuspid valve to form during Heart Embryology. Unequivocally a cyanotic congenital heart disease, it usually presents with decreased pulmonary blood flow.

Chapters:
00:00 - Introduction
00:18 - Heart embryology
02:37 - Circulation overview and necessary shunts
03:25 - Malformation anatomy
04:44 - Cyanotic heart disease with decreased blood flow
06:19 - Associations and classification
08:11 - Epidemiology
08:42 - Prognosis and differential diagnosis
09:36 - Diagnosis
10:18 - Surgical repair (Glenn and Fontan Procedures)

------------------------------------------------------------------------------------------------------------------------------------------------------------------
My Products and Services:
👕 MEDICAL-THEMED CLOTHING: https://betanhomartins.com/
🖼️ MEDICAL THEMED DÉCOR: https://displate.com/rbm_md?art=66d21...
📞 CLASSES and CONSULTING appointments: https://rbmmd.setmore.com/

Social Media:
🌴 Linktree: https://linktr.ee/rbm_md
📸 Instagram:   / rbm_md  
🐦 X:   / rbm_md  
📃 Facebook:   / rbm.md  
🎥 Odysee: https://odysee.com/@RBM,MD:2
📱 TikTok:   / rbm_md  
👔 LinkedIn: https://bit.ly/RBM-LinkedIn
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

Tricuspid atresia is a severe cyanotic congenital heart disease characterized by the absence or complete closure of the tricuspid valve. Understanding tricuspid atresia anatomy reveals a critical structural defect where no direct connection exists between the right atrium and right ventricle. This anomaly profoundly impacts normal cardiac physiology, leading to significant oxygenation issues and systemic cyanosis. Tricuspid atresia congenital heart defect represents approximately 1-3% of all congenital heart disease cases.

The embryological origins of tricuspid atresia involve abnormal development during early cardiac formation, specifically affecting the tricuspid valve region. Tricuspid atresia embryology indicates that disrupted differentiation processes result in anatomical absence of this vital valve. Consequently, the pathology of tricuspid atresia involves marked right ventricular hypoplasia and dependence on associated cardiac defects, such as atrial septal defects or ventricular septal defects, for survival.

Tricuspid atresia classification is based primarily on the associated cardiac anomalies and the status of pulmonary blood flow, guiding both prognosis and management strategies. The prognosis of tricuspid atresia varies significantly based on timely diagnosis and severity of associated defects. While advancements in surgical interventions have improved outcomes, untreated cases typically present with profound cyanosis and life-threatening complications.

Treatment of tricuspid atresia typically involves staged surgical procedures, beginning shortly after birth. These interventions aim to improve blood oxygenation and establish stable systemic circulation. Common surgical treatments include the Blalock-Taussig shunt in infancy, followed by subsequent operations like the Glenn procedure and ultimately the Fontan procedure. Accurate anatomical understanding is vital, making resources such as tricuspid atresia animation essential educational tools.

Tricuspid atresia physiology underscores the critical dependence on interatrial communications for systemic blood flow, as right-sided circulation is severely compromised. Resources such as tricuspid atresia animations effectively illustrate this complex physiology, aiding healthcare professionals and patients in comprehending disease mechanisms and treatment rationales. Continuous advances in surgical and medical treatments continue to improve the long-term prognosis for individuals affected by this challenging congenital heart disease.